[New antimicrobials against Gram-positive organisms]

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Glycopeptides are mainstays for Gram-positive infections, including MRSA.
• Increasing glycopeptide resistance and tolerance (e.g., VISA) pose significant clinical challenges.
• Vancomycin failure is linked to elevated MICs and increased mortality.

Purpose of the Study:

• To review emerging antimicrobial agents for Gram-positive bacterial infections.
• To highlight new treatment options for infections caused by resistant pathogens.
• To discuss agents suitable for empirical use and outpatient settings.

Main Methods:

• Literature review of current and developing antimicrobial therapies.
• Analysis of antimicrobial efficacy against susceptible and resistant Gram-positive strains.
• Evaluation of drug properties including dosing, safety, and interactions.

Main Results:

• Several new agents show promise against MRSA and other resistant Gram-positive organisms.
• Daptomycin, linezolid, tigecycline, and quinupristin/dalfopristin are current options.
• New glycopeptides, ceftobiprole, and iclaprim are under development.

Conclusions:

• Novel antimicrobials are crucial to combat rising resistance to glycopeptides.
• Effective management of resistant Gram-positive infections requires diverse therapeutic options.
• Ongoing research is vital for developing next-generation anti-Gram-positive agents.